P.I.-WORKS
20.4.2021 07:02:11 CEST | Business Wire | Press release
Beeline, Russia’s established mobile operator, has partnered with P.I. Works on network planning project, aimed at streamlining the operator’s investment planning processes and revolutionizing customer experience. As a part of the project, P.I. Works SmartPlan, the cutting-edge automated and AI driven network planning solution, will be deployed nationwide.
Prior to this agreement, P.I. Works provided network planning services for Beeline, which exemplified the SmartPlan’s Return on Investment and Service Quality based planning capabilities. This initial project covered three of Russia’s branches, Moscow, Krasnodar and Novosibirsk, and optimized investments by 19% for high-level technical calculations and resulted in a reduction of 23% of the number of planned sites with LTE extensions. These results highlight the investments that Beeline Russia is making in data networks, and supports the possibility of improving time-to-market, thereby paving the way to a nationwide full-scale automated network investment planning project.
Valeriy Shorzhin, Executive VP, CTO Beeline said, “With customer experience at the forefront of everything we do, network investment planning has never been more fundamental to meeting our strategic objectives. Our aim is to achieve these while maximizing investment cost efficiencies and reducing the planning cycles. After the SmartPlan system is implemented, we intend to undertake in-depth analysis of the data coming from multiple sources in automatic mode. This gives us possibility to calculate high-level site and extension plans with high accuracy in automated mode. We expect this to create a more time-efficient investment planning process, provide more transparent calculations, and enable more structured processes given the intelligent automation capabilities of the system. We are confident that our partnership with P.I. Works will open up new opportunities for both companies.”
P.I. Works’ proprietary Smart Network Planning solution incorporates business and network metrics into a single solution to effectively forecast the network traffic volume and plan future investment decisions. It also uses inputs like Network KPIs, physical site data, point-of-interest locations, crowdsourced data, marketing data and other customer centric data to generate a priority model for investment planning decisions in line with Beeline’s planning policies.
SmartPlan solution orchestrates the investment requirements of different business units in a single platform and incorporates all layers and technologies into one process. This avoids separate planning processes for different business programs and requirements, thus eliminating redundant site investment. The solution also prioritizes the new site investments per region and technology based on Beeline’s planning policies.
Bülent Koca, Sales Director at P.I. Works said, “Teaming up with Beeline has once again proved the success of our commendable track record in network automation. We are proud to be able to cater for the needs of our partner, with the support of our unparalleled network planning offerings. We strongly believe that SmartPlan system will radically transform Beeline’s customer experience levels, all while keeping costs in check.”
About and Disclaimer
https://pi.works/2Qcjnde
View source version on businesswire.com: https://www.businesswire.com/news/home/20210419005319/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
